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Metabolic syndrome (MetS) represents a cluster of metabolic and cardiovascular complications, 
including obesity and visceral adiposity, insulin resistance, dyslipidemia, hyperglycemia and 
hypertension, which directly increase the risk of cardiovascular diseases (CVD) and diabetes 
mellitus type 2 (DM2). Patients with arthritic diseases, such as rheumatoid arthritis and 
osteoarthritis, have a higher incidence of CVD. Although recent advances in the treatment of 
arthritic diseases, the incidence of CVD remains elevated, and MetS has been identified as a 
possible link between CVD and arthritic diseases. Chronic low-grade inflammation associated with 
obesity has been established as a significant contributing factor to the increased prevalence of 
MetS. Adipokines, which play important physiological roles in metabolic activities contributing to the 
pathogenesis of MetS, are also involved in the regulation of autoimmune and/or inflammatory 
processes associated with arthritic diseases. Therefore, MetS and dysregulated secretion of pro-
inflammatory adipokines have been recognized as a molecular link between CVD and arthritis 
diseases. In the present paper, we review recent evidence supporting the role played by 
adipokines, in particular leptin, adiponectin, and lipocalin-2, in the modulation of the immune 
system, MetS and arthritic diseases. The underlying cellular and molecular mechanisms are 
discussed, as well as potential new therapeutic strategies. 
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 Metabolic syndrome (MetS) refers to a cluster of metabolic abnormalities including obesity, 
insulin resistance (IR), dyslipidemia, hyperglycemia, and hypertension. These factors directly 
increase the risk of cardiovascular morbidity and mortality, by approximately two times  as those 
without the syndrome [1], as well as diabetes mellitus 2 (DM2), with around five-fold greater risk 
[2]. MetS lacks a universally accepted definition since different medical associations disagree with 
diagnostic criteria [3]. In 2009, the International Diabetes Federation and the American Heart 
Association/National Heart, Lung, Blood Institute (AHA/NHLBI) have developed a unified clinical 
definition. Accordingly, insulin resistance is not a crucial factor for MetS diagnosis, but a patient 
should have at least 3 among the 5 following criteria: visceral obesity, elevated blood pressure, 
high triglyceride levels, low high-density lipoprotein cholesterol (HDL-C) levels and/or elevated 
fasting glucose [4]. It is estimated that MetS concerns 10%-40% of the population varying 
according to the diagnostic criteria, gender, age, genotype, ethnicity, lifestyle, diet, and physical 
activity [5]. Moreover, MetS prevalence is rapidly increasing with lifestyle modifications, such as 
increased calorie intake, reduced physical activity, and sedentary conduct, and has been related to 
high incidence pathologies related to obesity, including fatty liver disease, polycystic ovary 
syndrome, osteoarthritis or rheumatoid arthritis [5]; thus, becoming one of the major health 
problems in industrialized countries. 
 As denoted, MetS underlies a complex and diverse range of pathologic conditions. 
However, the etiology and the cellular and molecular mechanisms of MetS and its components still 
need to be clearly understood. Chronic inflammation associated with obesity has been established 
as a significant factor underlying the pathophysiology of insulin resistance and MetS [6]. Obesity, 
and especially the expansion of visceral fat depots, leads to a 'chronic low-grade inflammatory 
state' [7] characterized by a deregulated secretion of adipose tissue-derived factors, i.e. 
adipokines. Altered synthesis and secretion of adipokines are associated with cellular changes in 
adipose tissue, namely adipocyte hypertrophy, phenotype and localization of immune cells, 
vascular and structural cells [7]. Moreover, the expression of these biologically active proteins 
varies with the site of WAT depot. In particular, the expansion of visceral WAT is associated with 
increased levels of adipokines [8]. High-calorie diets can also promote a pro-inflammatory state 
and thus adipokine production in WAT multi-depot organ, such as heart, kidneys or adventitia of 
major blood vessels [8]. Interestingly, adipokines secretion by epicardial adipose tissue has been 
associated with coronary artery disease, MetS, and DM2 [9]. Adipokines have also been described 
to affect the insulin sensitivity in liver, skeletal muscles and adipose tissue itself, and to be involved 
in the regulation of the innate and adaptive immune system. Moreover, pro-inflammatory 
adipokines are involved in endothelial dysfunction and atherosclerosis, being pointed out as 
important players in cardiovascular disease (CVD) [10]. Thus, adipokines provide a connection 
between the inflammatory state of MetS, IR and endothelial dysfunction. 




arthritic diseases, namely osteoarthritis (OA) [11] and rheumatoid arthritis (RA) [12]. Although the 
recent advances in the treatment of arthritis diseases, the CVD incidence in these patients remains 
elevated, and MetS has been pointed as an underlined responsible. Moreover, as important 
modulators of bone and cartilage metabolism as well as immune responses, adipokines have been 
described as key factors in the pathophysiology of arthritis diseases [13]. The present review 
discusses the recent data on the inter-relations between arthritis diseases and metabolic syndrome 
or CVD, evidencing adipokines as molecular linkers (Figure 1). A better understanding of 
pathophysiologic mechanisms of MetS and arthritis diseases is mandatory to develop efficient and 
safe treatments against the progression of these diseases and their associated comorbidities. 
 
2. Metabolic syndrome and arthritis diseases 
 Osteoarthritis, the most common form of arthritis, is a progressive degenerative and 
multifactorial disease of the entire joint, affecting the articular cartilage, meniscus, ligaments, bone, 
and synovium. It is characterized by molecular, anatomic, and/or physiologic derangements, 
including abnormal metabolism of joint tissues, cartilage degradation, bone remodeling, osteophyte 
formation, inflammation and loss of normal joint function [14,15]. It has been verified that the 
prevalence of MetS is higher in OA subjects [16,17]. Inflammation, oxidative stress, common 
metabolites, and endothelial dysfunction were proposed to link metabolic OA aetiologically to MetS 
[18]. Moreover, Zhuo and co-workers proposed that metabolic OA should be a new facet of MetS 
definition, evidenced by the strong associations and shared mechanisms with MetS components, 
such as hypertension, dyslipidemia, hyperglycaemia and obesity [18]. Furthermore, obesity, the 
main MetS risk factor, is also a well-known risk factor for OA incidence, progression, and disability. 
Besides the patent biomechanical effect of overweight on the joint, there is increasing evidence 
that a metabolic component links obesity with OA [19]. In particular, adipokines have been 
highlighted as important modulators of joint homeostasis implicated in the pathogenesis of OA 
[20,21].  
 Rheumatoid arthritis is a chronic inflammatory joint disease defined by synovial membrane 
inflammation and hyperplasia ("swelling"), destruction of cartilage and bone ("deformity"), 
production of autoantibodies (rheumatoid factor and anti-citrullinated protein antibody) - 
autoimmune disease, and systemic features like pulmonary, skeletal, cardiovascular, and 
psychological complications [22,23]. It was verified that MetS is commonly present in RA patients 
[12,24] and that the risk of developing moderate-to-severe RA was higher in patients with MetS 
than those without it [25]. Furthermore, the disease activity was related to the number of MetS 
parameters present, indicating that MetS might have inflammatory milieu that promotes the 
occurrence of more severe RA [25]. These data indicated the presence of common modulators 
cross-linking MetS and RA. Accordingly, adipokines have been indicated as modulators of 
metabolic disorders as well as autoimmune rheumatic diseases [13,20].  




actions of leptin, adiponectin, and lipocalin-2 in immunity as well as in MetS and arthritis diseases. 
A schematic representation of adipokines as molecular linkers between metabolic syndrome, 
immune system, and arthritic diseases can be found in Figure 1, while Table 1 overviews their 
biological activity in multiple organs. 
 
3. Leptin 
 Leptin, the forerunner and best-characterized member of the adipokine family, is a 16 kDa 
non-glycosylated cytokine-like hormone encoded by the obese (ob) gene, the murine homolog of 
human LEP gene [26]. Leptin is mainly produced by adipocytes and thus, its levels are mostly 
dependent of the white adipose tissue (WAT) mass and body mass index, but some inflammatory 
factors can also modulate leptin synthesis [27]. This hormone regulates food intake and energy 
consumption by inducing anorexigenic factors and suppressing orexigenic neuropeptides on 
hypothalamic nuclei [28]. In fact, mutations in either ob or db gene (encoding leptin and leptin 
receptor, respectively) result in severe obesity in murine models. Moreover, leptin is also implicated 
in other physiologic functions, like insulin secretion, atherosclerosis, bone and cartilage 
metabolism, inflammation, infection and immune responses [20,29]. Accordingly, leptin receptors 
[LEPR; or Ob receptors (Ob-R)] is expressed throughout the cells of innate and adaptive immune 
system, blood vessels, as well as cardiomyocytes, suggesting leptin as an important linker of 
neuroendocrine, cardiovascular and immune systems [29,30]. 
 Leptin receptors , are a class I cytokine receptor family from diabetes (db) gene [31]. There 
are at least six Ob-R isoforms that possess identical extracellular binding domains but differ in the 
length of the cytoplasmic domain: a soluble isoform (Ob-Re), four short isoforms (Ob-Ra, Ob-Rc, 
Ob-Rd and Ob-Rf), and a long isoform (Ob-Rb), which has a full intracellular domain that allows 
the transduction of signal via Janus kinase (JAK) and signal transducer and activator of 
transcription (STAT) signaling pathways [32]. Alternatively to the canonical JAK/STAT pathway, 
leptin receptors also signal via extracellular signal–regulated kinases (ERK) 1/2, p38 mitogen-
activated protein kinase (MAPK), c-Jun N-terminal kinases (JNK), Protein kinase C (PKC), Src 
homology region 2-containing protein tyrosine phosphatase 2 (SHP2)/ Growth factor receptor-
bound protein 2 (GRB2) and Phosphoinositide 3-kinases (PI3K)/Akt pathways [20,28]. In humans, 
common obesity is frequently characterized by hyperleptinemia and unresponsiveness to 
exogenous leptin administration. This leptin resistance state is possible derived by a decreased in 
the levels of cell surface Ob-Rb, down-regulation of positive regulators or up-regulation of negative 
regulators, including suppressor of cytokine signaling 3 (SOCS-3) and protein tyrosine 
phosphatase 1B (PTP1B) [20,28,31]. Therefore, it is important to take into account leptin 
responsiveness when interpreting the leptin effects in peripheral tissues as well in the development 
of leptin-directed therapeutic approaches. 
 




 Leptin has been described as a potent regulator of the immune system (extensively 
reviewed in [20]). In innate immunity, leptin can augment the cytotoxicity of natural killer (NK) cells, 
and the activation of granulocytes,  namely neutrophils, basophils and eosinophils, as well as 
macrophages and dendritic cells (DCs), thus exacerbating and perpetuating inflammatory 
conditions [20]. Leptin enhanced immature NK survival through Bcl-2 and Bax gene modulation 
[33] and increases NK cytotoxicity via STAT3 activation and expression of IL-2 and perforin [34]. In 
neutrophils, leptin mediates chemotaxis and infiltration via p38 MAPK and Src kinases [35], and 
induces survival by delaying the cleavage of Bid and Bax, mitochondrial release of cytochrome C 
and activation of caspase-3 and -8 through PI3K, NF-κB and MAPK pathways [36]. Leptin 
enhances the release of pro-inflammatory mediators IL-1β, IL-6, IL-8, and MCP-1, up-regulates the 
expression of cell surface adhesion molecules ICAM-1 and CD18 while down-regulates ICAM-3 
and L-selectin [37] in eosinophils. Moreover, this hormone acts as an eosinophil survival factor by 
delaying their apoptosis via JAK, NF-κB and p38 MAPK signaling pathways [37]. In basophils, 
leptin-induced migratory activity promoted IL-4 and IL-13 secretion, increased the cell surface 
expression of CD63, and augmented basophils degranulation in response to aggregation of IgE or 
its high-affinity receptor FcεRI [38]. Thus, leptin has a positive action in cell survival, cytokines 
release and chemotaxis of neutrophils, eosinophils, and basophils. Accordingly, in obese 
hyperleptinemic individuals, neutrophils have increased superoxide release and chemotactic 
activity [39], and eosinophils demonstrate greater adhesion and chemotaxis towards eotaxin and 
CCL5 [40]. Moreover, in these individuals, NK function is impaired compared to lean subjects, likely 
due to the development of leptin resistance [41],  
 In macrophages, leptin treatment promoted phagocytic activity, via modulation of cAMP 
levels [42], intracellular ROS generation [43], and chemotactic responses, through intracellular 
calcium influx, JAK/STAT, MAPK and PI3K pathways [44]. Furthermore, leptin-treated human 
macrophages had increased M2-phenotype surface markers but were able to secrete M1-typical 
cytokines,  like TNF-α, IL-6, IL-1β. IL-1ra, IL-10, and MCP-1, indicating a role for leptin in the 
determination of the adipose tissue macrophages phenotype [45]. Leptin acts as an activator of 
human DCs by up-regulation of IL-1β, IL-6, IL-12, TNF-α, and MIP-1α production, increasing the 
immature DC migration and their chemotactic activity, licensing them towards Th-1 priming [46]. 
Moreover, leptin induces DC survival by reducing apoptosis via modulation of NF-κB, PI3K/Akt, 
Bcl-2 and Bcl-xL [47,48]. The role of leptin in DC activation, chemoattraction, and survival, with 
further implications on DC maturation ad migration was also verified in Lepr-deficient (db/db) and 
leptin-deficient (ob/ob) murine models [47,49,50]. 
 The functions of leptin in adaptive immunity were first evidenced using ob/ob and db/db 
mice, which demonstrated thymus atrophy, T-cell lymphopenia, and reduced delayed-type 
hypersensitivity, which were reversed by leptin administration in ob/ob mice [49–51]. Later on, the 
effect of leptin in T and B cell biology have been extensively studied. Leptin promoted the 




proliferation of Foxp3+CD4+CD25+ T regulatory (Treg) cells [54]. Accordingly, morbidity obese 
children (congenitally leptin-deficient) had decreased number of circulating CD4+ T cells, and 
impaired T cell proliferation and cytokine release, which were rescued by treatment with 
recombinant human leptin [55], and obese subjects demonstrated a reduced number of 
CD4+CD25+CD127-Foxp3+ Treg cells [56]. Leptin also promoted CD4+ T cell polarization towards 
a pro-inflammatory Th1 phenotype, which secretes IFNγ and IL-2, rather than anti-inflammatory 
Th2 response, which secretes IL-4 [57]. Furthermore, articular injection of leptin enhanced Th17 
cells in joint tissues in collagen-induced arthritis mice model, leading to the exacerbation of 
inflammation and early onset of arthritis [58]. It was verified that leptin modulated Th17 cells 
differentiation via retinoic acid-related orphan receptor (ROR)γt and STAT3 activities [59]. Thus, 
leptin diminishes Treg proliferation, whereas it augments Th17 cell proliferation and 
responsiveness, pointing out the therapeutic potential of the leptin system in autoimmunity and 
inflammation. In B lymphocytes, leptin promoted cell homeostasis via suppression of apoptosis and 
induction of cell cycle entry via activation of Bcl-2 and cyclin D [60], and mediated the release of 
pro- (TNF-α and IL-6) and anti-inflammatory (IL-10) cytokines through JAK/STAT and p38MAPK-
ERK1/2 pathways [61]. Accordingly, db/db and ob/ob mice had a reduced number of peripheral 
blood and bone marrow B lymphocytes. Moreover, fasted mice, characterized by low serum leptin 
levels, presented a decreased number of pro-B, pre-B and immature B cells and increased levels 
of mature B cells in bone marrow, all reversed after leptin administration [60–62]. 
 
3.2. Leptin and metabolic syndrome 
 It is widely accepted that elevated leptin levels -hyperleptinemia- are correlated with MetS 
and cardiovascular diseases, including atherosclerosis, hypertension, stroke and myocardial 
infarction [65] (Figure 2). The high-fat induced rodent model of metabolic syndrome presented 
hyperleptinemia, hyperinsulinemia, increased body weight and energy intake, impaired glucose 
tolerance, as well as cardiovascular complications, like endothelial dysfunction, cardiac fibrosis, 
and cardiac hypertrophy [66,67]. Accordingly, hyperleptinemia was observed in both male and 
female patients with metabolic syndrome [68], and variations on leptin concentrations were 
correlated with MetS score in Taiwanese adults [69]. In fact, leptin levels were pointed out as an 
obesity-independent predictor of MetS development, which could be related to the development of 
glucose intolerance and insulin resistance [70]. Moreover, leptin levels were positively correlated 
with insulin resistance and triglycerides concentration, and negatively correlated with HDL-
cholesterol, typical parameters for early signs of MetS [71]. The leptin-deficient ob/ob mice model 
developed cardiomyopathy evidenced by impaired cardiac relaxation and contractility, partially due 
to augmented apoptosis and deregulation of intracellular Ca2+ reuptake in sarcoplasmic reticulum 
[72]. In patients with acute ischemic stroke, elevated leptin levels were more often present in 
patients with metabolic syndrome, being pointed as an independent risk factor for stroke in obese 




which were as an independent risk factor for disease development [73]. Noteworthy, in a 20-year 
follow-up study, little association was found between leptin, the prevalence of metabolic syndrome 
and cardiovascular death [74]. Moreover, some studies evidenced a cardioprotective role for leptin 
by attenuation of cardiac apoptosis and thus protecting against experimental and clinical ischemia, 
likely through JAK/STAT3 and AMPK activation [73–75]. Altogether, these findings indicated that 
leptin may be a double-edged sword for the cardiovascular system and further studies are needed 
to clarify the actions mechanisms of leptin and the role of hyperleptinemia in CVD under obesity 
and MetS. 
 
3.3. Leptin and arthritic diseases 
 Besides to its well-known role on immune responses, leptin has been described as a 
central factor in the pathophysiology of arthritic diseases due to its ability to modulate bone and 
cartilage metabolism [20] (Figure 2).  
 
3.3.1. Osteoarthritis 
 Leptin has been extensively associated with cartilage metabolism and OA. OA human 
chondrocytes produced higher levels of leptin than from normal cartilage[78], being the pattern of 
leptin expression related to the grade of cartilage destruction [79,80]. Moreover, the leptin levels 
were found elevated in serum, IPFP, synovial tissues and cartilage of OA patients compared with 
healthy controls [81,82]. Very recently, the leptin-induced OA phenotype was correlated with the 
up-regulation of inflammatory mediators, MMPs, growth factors and osteogenic genes [83]. 
Accordingly, the NEIRID lab demonstrated that leptin, in synergy with IL-1β, induced the 
expression of pro-inflammatory factors, such as IL-6, IL-8, NO, NOS2, PGE2, and COX2 in 
chondrocytes [84]. Recently, it was demonstrated that leptin also regulates the production of IL-6, 
IL-8, and CCL3 by CD4+ T cells in OA patients, but not in healthy individuals [85], revealing new 
action mechanisms of leptin in the immune system and OA pathophysiology. Besides regulating 
pro-inflammatory mediators expression, leptin also leads to OA-related joint destruction by 
inducing MMPs expression. In particular, MMP-1, -2, -3, -8, and -13, ADAMTS4 and S5, while 
proteoglycan and FGF2 were reduced [86]. Leptin is also responsible for the perpetuation of 
cartilage degradation through VCAM1 induction in human primary chondrocytes, which induces the 
migration of leukocytes and monocytes to inflamed joints via chemoreceptors activity [27]. Of late, 
the role of microRNA miR-27, which directly targets the 3'-untranslated region of leptin, in OA has 
been evidenced. OA chondrocytes presented low levels of miR-27 and the overexpression of this 
microRNA in a preclinical model of OA in rats led to increased levels of IL-6, IL-8, MMP-9 and 
MMP-13. This indicated the potential protective role of miR-27 likely by targeting leptin [87]. Leptin 
also modulated osteoblast function and thus bone metabolism leading to joint destruction in OA 
patients [21,88]. Altogether, this data pointed out leptin as an important modulator of inflammation, 






3.3.2. Rheumatoid arthritis 
 Leptin has been implicated in RA development; however, there are contradictory results and 
large cohort studies are necessary. It was verified that leptin levels were elevated in RA patients, 
being its synovial fluid and serum levels correlated with disease duration, radiographic joint 
damage, and parameters of RA activity (Olama, Senna, and Elarman 2012). However, leptin has 
also been associated with reduced radiographic joint damage [90], which could be related to the 
anabolic action of leptin [78]. Leptin-deficient mice evidenced a less severe antigen-induced 
arthritis, reduced levels of TNF-α and IL-1β, a defective cell-mediated immunity, and a shift towards 
Th2 cell response [91]. Interestingly, the reduction of leptin levels by fasting in RA patients 
improved the RA clinical symptoms [92]. Clinical studies evaluating the effect of PPARγ agonists () 
are ongoing to target inflammation and cardiovascular complications associated with RA [93]. Of 
note, these agonists are modulators of insulin sensitivity, which is affected by leptin levels. 
Moreover, leptin protein mutants with antagonist action as well as monoclonal antibodies against 
leptin and LEPR have been pointed out as promising therapeutic strategies for RA [94]. Therefore, 
deep knowledge of the leptin action mechanisms would be crucial for the treatment of RA. 
 
4. Adiponectin 
 Adiponectin, also called GBP28, apM1, Acrp30 or AdipoQ, is a 244-residue protein with 
structural homology to collagen type VIII and X, as well as complement factor C1q. This adipokine 
is mainly produced in adipose tissue and it is found in different molecular forms: the globular 
adiponectin (gAPN), the full-length adiponectin (fAPN), the low MW (LMW) adiponectin, the 
medium MW (MMW) adiponectin, the high MW (HMW) adiponectin, and the serum albumin 
bonded LMW form (Alb-LMW) [95,96]. Adiponectin acts specifically through two receptors, the 
AdipoR1, predominantly present in the skeletal muscle, and AdipoR2, mainly found in the liver. 
Binding to Adipo receptors leads to activation of AMPK, PPAR-α and -γ, among other signaling 
pathways [96]. In morbidly obese patients, circulating levels of adiponectin tend to be low and 
increase after weight loss or treatment with thiazolidinediones (PPAR agonists), which enhance 
insulin sensitivity [96]. In fact, adiponectin works as an endogenous insulin sensitizer by stimulating 
glucose uptake via an increase of fatty acid oxidation and reduction of glucose synthesis in the 
liver. AMPK signaling has been implicated in the insulin-sensitizing activity of adiponectin in the 
liver, while AMPK, PPAR-α, and Ca2+ are involved in adiponectin ability to modulate fatty acid and 
glucose metabolism [96]. Adiponectin knockout mice develop severe insulin resistance and exhibit 
lipid accumulation in muscles when placed on a high-fat/sucrose diet, however, no dramatic effects 
were observed when placed in a normal diet [97]. In fact, adiponectin is encoded by the ADIPOQ 
gene located on the chromosome 3q27, a locus linked with susceptibility to develop diabetes and 




inflammation-related diseases, namely CVD, T2DM, MetS, OA and RA, likely due to its action on 
the innate and adaptive immune system [98] (Figure 2). 
 
4.1. Adiponectin in innate and adaptive immunity 
 Adiponectin has been recognized as an important modulator of the immune system, but 
whether it acts as pro- or anti-inflammatory adipokine is still a matter of intense debate. In 
macrophages, adiponectin was demonstrated to suppress differentiation and classical M1 
activation via down-regulation of pro-inflammatory cytokines, like TNF-α, IL-6, and CCL2, whereas 
it promotes M2 proliferation and activation leading to the expression of anti-inflammatory cytokines, 
namely arginase-1, IL-10 and Mgl-1 [98]. This adipokine also regulates the activity of neutrophils, 
eosinophils, NK cells and DCs [98,99]; however, it remains unclear if the cell's functions are 
positively or negatively regulated by adiponectin. These apparent paradoxical, dual effects might 
be related to different adiponectin configurations [95]. In particular, gAPN but not fAPN adiponectin 
impaired LPS-induced ERK1/2 activation in Kupffer cells, while gAPN and HMW but not MMW or 
LMW augments NF-κB activation in monocytic cells [95]. 
 In adaptive immunity, adiponectin was described to activate plasma B cells and stimulate B 
cell-derived peptide PEPITEM secretion, thus inhibiting the migration of memory T cells [100]. 
Adipo receptors are up-regulated after T cells activation and adiponectin leads to decreased 
antigen-specific T cell proliferation and cytokine production through augment of T cell apoptosis 
[101]. Furthermore, adiponectin enhances Th1 differentiation and DCs, treated with adiponectin, 
induced both Th1 and Th17 responses in allogenic T cells, contributing to enhanced pro-
inflammatory responses [101]. A deeper understanding of the adiponectin's effects and 
mechanisms in innate and adaptive immune cells will be of relevance for developing new 
therapeutic strategies directed against adiponectin system. 
 
4.2. Adiponectin in metabolic syndrome  
 Unlike most of the other adipokines, adiponectin seems to have a protective role in MetS 
and T2DM. Circulating adiponectin levels are decreased in patients with obesity, coronary artery 
disease, diabetes, and hypertension, as well as in IR and diabetic animals [100–103], and 
increased with weight loss [106], physical training [107], and the use of insulin-sensitizing drugs 
[106]. This suggests that obesity-related hypoadiponectinemia is reversible [108]. Moreover, 
adiponectin secretion is inhibited by pro-inflammatory factors, like IL-6 and TNFα [109], indicating 
the potential role of inflammation in the development of hypoadiponectinemia associated with IR 
and obesity. Adiponectin was also negatively correlated with triglyceride levels whereas positively 
associated with plasma HDL levels, even in the absence of other MetS risk factors [110,111]. In 
fact, several studies indicated adiponectin as MetS biomarker. A strong negative correlation 
between the MetS score and serum adiponectin levels has been verified [112]. In a prospective 




incidence of MetS [113]. Patients with nascent MetS, and thus without confounding CVD and/or 
T2DM, presented lower adiponectin levels than controls [114]. Moreover, low adiponectin plasma 
levels have been demonstrated to predict IR and T2DM [102,115,116]. Consequently, normal or 
even elevated adiponectin concentrations are considered to be protective against MetS and T2DM 
[117]. Adiponectin administration reduced the plasma glucose levels by improving the insulin action 
in diabetic and healthy mice [115–117].  
 As mentioned above, obesity, the major risk factor of MetS, is characterized by altered 
secretion of adipokines. Accordingly, adiponectin gene expression and circulating levels were 
inversely correlated with adiposity and waist circumference (WC) in patients with MetS, where 
intra-abdominal fat mass was found to affect the levels of circulating adiponectin [1,120]. Lower 
adiponectin levels were also found in obese patients with MetS, and in visceral obesity, which is 
negatively associated with IR [116,121], and in [122]. Adiponectin concentrations have also been 
inversely associated with endothelial dysfunction, hypertension, and markers of vascular 
inflammation, and thus, with CVD [121–123]. In particular, epidemiological data pointed 
hypoadiponectinemia as a predictor of imminent myocardial infarction [126,127] or hypertension 
development [128]. Furthermore, patients with arthritis and MetS demonstrated lower levels of 
adiponectin that arthritic patients without MetS. In RA patients, low adiponectin levels were 
suggested to be implicated in the development of RA-associated CVD [129]. Moreover, it was 
verified that in RA patients undergoing anti-TNFα therapy, the adiponectin concentrations were 
independently and inversely correlated with high-grade inflammation, via a mechanism not likely to 
be mediated by TNF-α [129]. 
 
4.3. Adiponectin in arthritic diseases 
4.3.1. Osteoarthritis 
 Adiponectin has been evidenced to be implicated in the pathophysiology of OA. Serum and 
plasma levels of adiponectin were increased in OA patients, compared to healthy subjects [130], 
being higher in patients with radiologically most severe OA disease [131], as well as in patients 
with erosive OA in relation to non-erosive OA [132]. In fact, adiponectin was proposed as a 
biomarker for OA [133]. Moreover, adiponectin serum levels have been correlated with OA 
biomarkers and local synovial inflammation [131,134]; however, no association with radiographic 
hand OA was observed [135]. This adipokine could be expressed by synovial fibroblasts, IPFP, 
osteophytes, cartilage, and bone tissues within the joint [136], and its levels in OA synovial fluids 
were correlated with aggrecan degradation [137]. Most of the results indicated a pro-inflammatory 
and catabolic action of adiponectin by increasing the production of NO, IL-6, IL-8, VCAM-1, TIMP-
1, MMP-1, -3, and -13 [82,129,136–138], which lead to cartilage degradation and OA 
pathogenesis. Nevertheless, a protective role for adiponectin in the OA pathogenesis has also 
been reported. In particular, this adipokine down-regulated IL-1β-induced MMP-13 expression and 




lower in a spontaneous animal OA model (STR/Otr mice) than in controls [142]. This contradictory 
evidence could be derived from patient heterogeneity, different study protocols, or the significance 
of adiponectin accordingly to the phase and severity of OA. Furthermore, exercise and mechanical 
loading were indicated as positive modulators of adiponectin levels, with potential effect in 
preventing bone loss [143,144]. Adiponectin was demonstrated to stimulate osteoclast proliferation 
and mineralization through bone morphogenetic protein (BMP)-2 and activation of p38 MAPK 
signaling [145,146], but there are contradictory results [147]. Altogether, the present data indicated 
that adiponectin modulated cartilage and bone metabolism, as well as biomechanical properties of 
the joint. However, further studies are necessary to clarify the exact role of this adipokine in OA 
pathogenesis. 
 
4.3.2. Rheumatoid arthritis 
 Adiponectin has also been evidenced as a modulator of RA pathophysiology. RA patients 
demonstrated increased serum and synovial adiponectin levels compared with healthy individuals, 
being its baseline levels predictive of RA radiographic progression [90,148,149]. Accordingly, it has 
been verified that adiponectin, alone or in combination with IL-1β, increases the production of 
inflammatory mediators, including IL-6, IL-8, and PGE2, in RA synovial fibroblasts [86,149]. The IL-
6 production induced by adiponectin is dependent on Adipo1R/AMPK/p38MAPK/NF-κB signaling 
pathway [86,149]. Interestingly, the anti-IL-6 receptor monoclonal antibody has been approved to 
RA treatment in several countries. Moreover, adiponectin induced the expression of MMP-1, MMP-
13, and VEGF in synovial cells and boosts joint inflammation through the induction of cytokine 
production and recruitment of immune cells into the synovium [86]. Therefore, adiponectin was 
pointed out as an important player contributing to synovitis and joint destruction in RA. However, in 
vivo data indicated that this adipokine demonstrated quite different actions in RA. In a preclinical 
model of collagen-induced mice arthritis, adiponectin administration mitigated arthritis severity 
along with a decrease in pro-inflammatory markers, such as TNF-α IL-1β, and MMP-13, in the joint 
[150]. Thus, further data from basic research and clinical observations in large-scale cohort studies 
will be fundamental to better elucidate the action of adiponectin in RA. 
 
5. Lipocalin-2 (LCN2) 
 Lipocalin-2 (also called neutrophil gelatinase-associated lipocalin-NGAL, p25, 24p3, 
migration-stimulating factor inhibitor, α-1-microglobulin-related protein, human neutrophil lipocalin, 
siderocalin or uterocalin) is a glycoprotein encoded by a gene located at the chromosome locus 
9q34.11 [151]. Initially identified in human neutrophils granules and mouse kidney cells [152,153], 
WAT is its major source. However, LCN2 is also expressed in immune cells, liver, spleen, and 
chondrocytes [154]. LCN2 circulates as a 25 kDa monomer, 46 kDa homodimer or as a covalent 
complex with MMP-9, blocking MMP-9 auto-degradation [155,156]. Two receptors have been 




and the transporter protein SLC22A17 (24p3R) that binds to mouse LCN2 [157]. Although less 
studied than leptin or adiponectin, LCN2 has been suggested as an important modulator of the 
immune system with potential implications in the pathophysiology of metabolic syndrome and 
arthritis diseases [13,21,158] (Figure 2). 
 
5.1. LCN2 in immune system 
 The members of lipocalin family posses a hydrophobic ligand binding pocket that confers 
the ability to bind and transport LPS, steroids, fatty acids, iron, and in the case of LCN2, 
siderophores [159,160]. By this way, LCN2 binds to enterobactin, a siderophore of Gram-negative 
bacteria responsible for iron transport. By depleting bacterial iron stores, which is essential for 
bacterial growth, LCN2 exhibits bacteriostatic activity with potential effects on the gastrointestinal 
tract protection against pathogens [161]. Besides its role in transport small lipophilic molecules, 
LCN2 has been implicated in the induction of hematopoietic cells [162] and in the modulation of the 
immune system. The promoter region of LCN2 comprises binding sites for key inflammatory 
transcription factors, namely NF-κB, C/EBP, STAT-1 and -3 [163]. In accordance with this, LCN2 
was described as an anti-inflammatory regulator of M1/M2 polarization through NF-κB/STAT3 loop 
activation [164]. Moreover, in adaptive immunity, LCN2 was described to induce human leucocyte 
antigen G (tolerogenic mediator) on CD4+ T cells, and to increase the expansion of T reg cells in 
healthy individuals [151]. Taking into account the immunoregulatory activity of LCN2, further 
studies should evaluate the therapeutic potential of LCN2 in immunosuppressive therapy efficacy, 
tolerance induction in transplants, and in immune system disorders, including MetS, CVD, OA, and 
RA. 
 
5.2. LCN2 in metabolic syndrome 
 The LCN2 concentrations have been associated with various metabolic and inflammatory 
parameters [149, 156, 163]. In particular, LCN2 circulating levels are positively correlated with 
adiposity, hyperglycaemia, insulin resistance, and hypertriglyceridaemia, but negatively associated 
with HDL cholesterol [165]. The LCN2 expression is generally increased in obesity and is reduced 
by thiazolidinedione treatment [151]. Moreover, there is increasing evidence suggesting that LCN2 
contributed to the development of obesity-related pathologies, like T2DM and CVD. Circulating 
LCN2 levels were increased in coronary heart disease patients [165]. Since LCN2 inhibits MMP9 
inhibition, its increased levels might lead to increased proteolytic activity and collagen degradation 
turning on atherosclerotic plaques into vulnerable plaques [165]. MetS patients demonstrated a 
significant correlation between insulin resistance and LCN2 levels [165]. Accordingly, serum LCN2 
levels were suggested as a useful biomarker for evaluating the clinical outcomes of obesity-related 
metabolic and cardiovascular complications [165]. 
 




 LCN2 can be produced at joint tissues in response to inflammatory mediators as well as to 
mechanical loading. In particular, LCN2 expression is augmented by IL-1β, LPS, dexamethasone, 
adipokines leptin, and adiponectin, as well as osteoblast conditioned medium in chondrocytes. Of 
note, NO controls the LCN2 expression in chondrocytes, indicating a feedback loop regulation of 
its expression. In osteoblasts, LCN2 is induced by TNF-α and IL-17, and by the absence of 
mechanical loading, likely contributing to bone metabolism through stimulation of osteoclastogenic 
factors, receptor activator of NF-κB ligand and IL-6, and inhibition of the osteoclastogenic factor 
osteoprotegerin [151]. 
 In OA patients, the synovial fluid is enriched with LCN2/MMP9 complexes that have been 
involved in the reduction of chondrocyte proliferation, as well as matrix and cartilage degradation 
[151,166]. Of late, glucocorticoids (commonly used in OA and RA treatment), alone or in 
combination with IL-1, have been demonstrated to increase LCN2 expression via corticoid receptor 
and PI3K, ERK1/2 and JAK2 pathways in immortalized mouse chondrocytes [167]. Moreover, 
transcription factor E74-like factor 3 and NF-κB also modulated LCN2 expression in chondrocytes 
[168]. Although these data indicated the involvement of LCN2 in joint pathophysiology, one study 
verified that LCN2 overexpression in mouse cartilage did not induce OA pathogenesis and that 
knockout of LCN2 did not affect cartilage destruction induced by medial meniscus destabilization in 
mice [169]. Therefore, even though LCN2 could contribute to OA pathophysiology, it is not 
sufficient by itself to initiate OA cartilage destruction. Further studies will be important to elucidate 
the action of LCN2 in the development of OA in humans. 
 RA patients displayed higher LCN2 levels than OA patients in synovial fluid [170]. Using 
proteome approaches, it has been verified that GM-CSF contributed to RA pathophysiology by 
increasing LCN2 expression in neutrophils, with consequent induction of transitional endoplasmic 
reticulum ATPase, cathepsin D and transglutaminase 2 in synoviocytes, which have potential 
implications in synovial cells proliferation and infiltration of inflammatory cells into the synovium 
[170]. However, the role of LCN2 in RA etiology and development remains largely unknown. 
 
6. Current and forthcoming therapeutic prospects 
 Currently available treatments for arthritis diseases show low efficacy, are frequently 
associated with adverse effects, and as far to achieve disease remission. Due to the lack of self-
healing capacity of articular cartilage, OA therapy is challenging and traditional pharmacologic 
therapies, such as acetaminophen, non-steroidal anti-inflammatory drugs, and opioids, are limited 
to pain relief [171]. Link MetS with OA evidenced the possibility of introducing new pharmacological 
interventions. Accordingly, thiazolidinedione and statins are being evaluated as supplements to 
symptom-alleviating NSAID treatment in OA [18]. However, well-designed, controlled studies for 
this novel use of conventional drugs are needed. 
 Currently, there is no cure for RA and treatment strategy focus on early diagnosis and rapid 




anti-rheumatic drugs (DMARD) have emerged, including TNF-inhibitor, anti-CD20 antibody, IL-6 
receptor antibody, RANKL antibody, and JAK inhibitor. But, long-term disease remission is not 
reached for many patients and therefore new therapeutic options are necessary [172]. Some RA 
treatments have been demonstrated to modulate adipokines levels. In particular, some studies 
indicated that TNF blockade increased adiponectin levels, but did not change circulating leptin 
levels [173]. Consequently, the leptin/adiponectin ratio, which is a marker of MetS and insulin 
resistance, can significantly decrease during biologic therapy [173]. 
 The relationships between MetS and rheumatic diseases are complex, encompassing a 
variety of influencing factors including obesity, cardiovascular function, metabolic status, and 
immune system. Accordingly, the treatment of arthritis pathologies seems to influence the risk of 
developing MetS and vice-versa [12]. Here, we evidenced adipokines as potential links between 
MetS, the immune system, and arthritis diseases (Figure 1). Thus, a better understanding of 
adipokines actions and mechanisms is of utmost relevance for developing effective therapies 
allowing to stop the progression of arthritic diseases as well as MetS and CVD, thereby improving 
the quality of life of the aging population. So far, the prevention of excessive weight gain must be 
the first line approach in the prevention of these high-incidence degenerative diseases. This 
strategy should be a social priority and require deep sociocultural changes, as well as international 
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Figure 1. Adipokines as molecular linkers between metabolic syndrome, immune system, 
and arthritic diseases. Body weight gain, accompanied by white adipose tissue 
expansion, lead to diabetes, obesity and associated chronic low-grade inflammation. 
Adipose tissue-derived adipokines cause cartilage degradation and osteoblast 
dysregulation in subchondral bone, thus promoting joint destruction. Adipokines also play 
important physiologic roles in metabolic activities contributing to the pathogenesis of 
metabolic syndrome. By inducing pro-inflammatory cytokine release from innate and 
adaptive immune cells, adipokines generated an inflammatory environment that prompts 
metabolic syndrome and arthritis diseases. 
 
Figure 2. Schematic representation of the biological effects of adipokines in metabolic 
syndrome and associated cardiovascular disease (CVD), as well as in arthritis diseases 
(osteoarthritis and rheumatoid arthritis). 
 
 
Table 1. Effects of leptin, adiponectin, and lipocalin-2 in multiple organs. 
 
 LEPTIN ADIPONECTIN LIPOCALIN-2 
LIVER 
 (+) correlation with IR and 
triglycerides concentration  
 (-) correlation with HDL-
cholesterol  
 (-) correlation with IR and 
triglycerides concentration  
 (+) correlation with HDL-
cholesterol  
 (+) correlationwith IR, hyperglycaemia, 
hypertriglyceridaemia  
 (-) correlation with HDL-cholesterol 
VASCULAR 
CELLS 
 ↓ cardiac apoptosis, through 
JAK/STAT3 and AMPK activation 
 (-) correlation with endothelial 
dysfunction, hypertension and 
markers of vascular inflammation 
 ↑ MMP9 proteolytic activity and 
collagen degradation leading to 
vulnerable atherosclerotic plaques 
IMMUNE 
CELLS 
 ↑ NK cytotoxicity  
 Activation of granulocytes, 
macrophages and DCs  
 Polarization of TH cells towards 
Th1 (pro-inflammatory 
phenotype) 
 ↓ Treg cells, ↑ Th17 cells 
 Modulation of innate immune 
cells activation  
 ↑ B cell activation and PEPITEM 
secretion  
 ↓ T cell proliferation and cytokine 
production  
  ↑ Th1 cells differentiation 
 Bacteriostatic effect via depletion of 
iron stores  
 Anti-inflammatory regulation of M1/M2 
polarization  
 ↑ Treg cell proliferation 
JOINT 
 ↑ pro-inflammatory factors 
(NOS2, COX-2, PGE2, IL6, and 
IL8) in chondrocytes  
 ↑ MMPs (MMP-1, -2, -3, -9, 
and -13, ADAMTS4, and 
ADAMTS5) 
 ↑ NO, IL6, IL8, VCAM1, TIMP1, 
MMP-1, -3, and -13 in 
chondrocytes  
 ↑ human osteoblast proliferation 
and mineralization  
 ↑ IL6, IL8 and PGE2 in RA synovial 
fibroblasts  
 ↑ MMP-1, MMP-13 and VEGF in 
synovial cells and promoted joint 
inflammation 
 Regulates bone metabolism: ↑ pro-
osteoclastogenic factors, ↓  anti-
osteoclastogenic factors  
 Induced by pro-inflammatory factors 
and glucocorticoids  
 Block MMP-9 auto-degradation  
 ↓ chondrocyte proliferation 
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